|
000
| 01791nam##2200265za#4500 |
|---|
| 001 | 9.645771 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210615112530 |
|---|
| 007 | ta |
|---|
| 008 | 150407|1995||||xxc||||| f|0| 0 eng|d |
|---|
| 020 | |a0-660-15911-2 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH42-2/67-1995E |
|---|
| 110 | 1 |aCanada.|bHealth Canada. |bDrugs Directorate. |
|---|
| 245 | 10|aMenopause : |ba report by the Special Advisory Committee on Reproductive Physiology to the Drugs Directorate, Health Protection Branch, Health Canada / |cChairman: Robert F. Casper. |
|---|
| 260 | |aOttawa - Ontario : |bHealth Canada. |c1995. |
|---|
| 300 | |a99p. : |breferences ; |c28 cm. |
|---|
| 500 | |aContents: Introduction.--Endocrinology of menopause.--The postmenopausal ovary and steroid metabolism.--Physiologic changes of menopause.--Management of the patient.--Risks of hormone replacement therapy.--Guidelines for hormone replacement therapy.--Conclusion.--Labelling. |
|---|
| 520 | 3 |aMenopause is not a disease state, but a transition in the life of every woman. Often misunderstood and shadowed in myth, it is a period of life that is often feared by women and their families. In addition to discussing various physiological changes, this report examines the risks, benefits and guidelines for prescribing hormone replacement therapy to delay the progression of osteoporosis and to prevent cardiovascular disease. Doctors and their patients face challenging decisions regarding treatment and counselling. With this report, health practitioners and women will have the latest medical opinions and knowledge to help come to terms with these changes. |
|---|
| 563 | |aSoftcover |
|---|
| 590 | |a95-23|b1995-06-09 |
|---|
| 690 | 07|aHealth|2gcpds |
|---|
| 720 | 1 |aCasper, Robert F. |
|---|
| 775 | 08|tLa ménopause : |w(CaOODSP)9.679402 |
|---|